H er －2阳性胃癌靶向治疗的研究进展

Progress of targeted therapy in Her-2 positive gastric cancer

化疗是治疗中晚期胃癌的有效方法，但单纯化疗不能明显改善中晚期胃癌患者的预后。随着对胃癌发生机制的深入研究，已经发现多个促使胃癌发生的“驱动基因”，针对这些“驱动基因”而设计的靶向药物也逐渐被研发。通过靶向抑制人类表皮生长因子受体2（ Her－2）来治疗胃癌，为中晚期胃癌患者提供了一种新的治疗方法。曲妥珠单抗（Herceptin），作为Her－2单克隆抗体，是一种治疗中晚期胃癌和转移性胃癌的靶向药物，它与以铂类和氟尿嘧啶类为基础的化疗药物联合使用，可以明显改善患者的预后。因此，本文就胃癌靶向治疗及靶向治疗联合化疗临床研究做一综述。

Although chemotherapy is an effective way for advanced gastric cancer ,it does not significant-ly improve the prognosis of patients .Recently ,further researches on the mechanism of gastric cancer have led to the identification of ′driver gene′and the development of new agents that target these genes .By inhibiting the hu-man epidermal growth factor receptor 2（Her-2）for advanced gastric cancer ,it provides a new treatment for pa-tients.Trastuzumab is a kind of Her -2 monoclonal antibody ,it is the first kind of targeted therapy drug for the treatment of advanced and metastatic gastric cancer .A combination of trastuzumab with cisplatin and fluorouracil based chemotherapy can benefit patients overall survival .Therefore,in this paper,we make a review and summary of a set of recent studies related to the gastric targeted therapy .